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BACKGROUND: Allergic inflammatory responses are
driven by cells of the immune system that rely on
cytokines to regulate the activity of other immune
and structural cells.
Objective: To review published studies to (1) identify
cytokines consistently increased after allergen chal-
lenge in atopic patients and (2) investigate temporal
variation in cytokine expression.
Methods: A PUBMED systematic search was used to
extract data from studies involving analysis of cyto-
kine expression in fluids or biopsies following in
vivo allergen challenge in atopic patients.
Results: Data were extracted from 82 studies. There
were no consistent reports of cytokine protein
increase in fluids of patients at 0 
/1 h after challenge.
At 4 
/12 h, the chemokines eotaxin, macrophage
inflammatory protein-1a, RANTES (regulated on acti-
vation normal T cell expressed and secreted) and
interleukin (IL)-8 have all been consistently reported
to be up-regulated. At 18 
/24 h after challenge, the
lymphokines IL-4, IL-5 and IL-13, as well as the pro-
inflammatory cytokines granulocyte 
/macrophage
colony-stimulating factor, tumour necrosis factor-a
and IL-6 are consistently increased when compared
with the respective control value. There were no
reports of up-regulation in interferon-g protein and
mRNA and in IL-2 mRNA.
Conclusion: The expression of granulocyte 
/macro-
phage colony-stimulating factor is consistently in-
creased in tissues at 4 
/12 h after challenge. The
influence of this cytokine on antigen capture and
presentation by dendritic cells should be further
investigated. Additionally, allergen challenge studies
are needed that investigate the expression of macro-
phage-derived chemokine and thymus-regulated and
activation-regulated chemokine in tissues of atopic
patients. Blocking the effects of these lymphocyte-
specific chemokines might provide new therapeutic
approaches for the control of allergic inflammation.
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Introduction
Allergic reactions result from an inappropriate re-
sponse of the immune system towards a group of
non-self-molecules collectively termed allergens.
1
This over-reaction of specific defence mechanisms
invariably triggers an inflammatory response that in
some cases can cause debilitating secondary effects
such as asthma.
2 Allergic inflammatory responses
involve both cells of the immune system and
structural cells of the injured tissue. To efficiently
restore homeostasis, the activity of these cells must be
integrated and coordinated. To a great extent, this
coordination involves cellular communication via
cytokine release.
Cytokines are extracellular signalling proteins pro-
duced by different cell types that act on target cells to
modulate diverse cellular functions.
3 Some cytokines
recruit specific cell types to the site of inflammation.
4
Others can act on immune cells to increase activation
and survival,
5,6 whereas some, like interferon (IFN)-g,
suppress cellular activity.
7 The role of cytokines in
mounting an adequate immune response is further
supported by the ability of lymphokines like inter-
leukin (IL)-4 and IL-13 to induce immunoglobulin
isotype switch in B cells
8,9 and to modulate T-cell
differentiation.
10 Therefore, identifying the pattern of
cytokine expression observed during the develop-
ment of an allergic inflammatory response provides a
valuable insight to the underlying immunological
mechanisms.
Bronchial, nasal and cutaneous allergen challenge
tests have been extensively used as a means of
investigating allergen-induced inflammation.
11 Since
the first studies published in 1991,
12,13 literally
hundreds of trials have investigated cytokine profile
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259following in vivo allergen challenge. In some cases,
conflicting results have been reported. This review
summarises data from these studies addressing the
following questions: Which cytokines are consistently
up-regulated in allergen challenged tissues of atopic
patients? Is there a time-dependent pattern of cyto-
kine expression? Finally, we discuss how these results
can be used to improve the understanding and the
control of allergic diseases.
Methods
Literature search
The PUBMED database was searched using the query
‘‘(allergen) AND (biopsy OR biopsies OR lavage* OR
fluid* OR section*) AND (interleukin* OR IL- OR
cytokine* OR chemokine* OR lymphokine*)’’, using
the limits Text Word, English and Human. This query
was performed in May 2002 and returned 292 titles
and/or abstracts.
Literature selection
The abstracts of these 292 articles were screened for
provisional inclusion in this review. Articles were
dropped from further analysis if they clearly did not
involve: (1) human subjects, (2) allergen challenge in
vivo and (3) collection of bronchial, nasal or cuta-
neous biopsies and/or fluids; review articles were
also eliminated at this step. This procedure yielded
147 articles,
12 158 of which five could not be obtained
in full text format.
154 158 The full text of the remain-
ing 142 articles was screened to identify studies that
included clinical trials involving: (i) the criteria (1) /
(3) described earlier, (ii) a cytokine baseline or
control value for each subject, and (iii) appropriate
cytokine quantitative data. This procedure resulted in
107 relevant studies
12 118 that were used for data
extraction. The main criterion for exclusion in this last
step was the absence of the aforementioned (iii)
(51%). Inappropriate data commonly resulted from
the absence of statistical comparison between base-
line or control cytokine values and the post-allergen
challenge value.
Data extraction
Several variables were extracted to characterise the
subjects and the clinical trial used in each of the 107
selected studies. These included number, disease and
atopy status of subjects challenged with allergen and,
to characterise the trial design, the challenge site
(lung/nose/skin), the allergen used, the specimen
collected (biopsy/fluid), the control used (baseline/
saline) and the time point of specimen collection
after the allergen challenge (0 /1 h/4 /12 h/18 /24 h).
In addition to these descriptive variables, the follow-
ing information for each cytokine analysed was also
extracted: control and post-allergen cytokine quanti-
fication, method for quantification and significance of
the variation (p value).
Data analysis
Analysis was restricted to patients; data from healthy
control subjects were not sufficient to allow proper
analysis. Data from patients undertaking immu-
notherapy or corticosteroid treatment were also
discarded. Each study contributed data more than
once to the analysis if it involved: (a) two or more
independent subject samples, (b) both biopsy and
fluid collection per subject sample, (c) two or more
cytokines analysed per specimen, or (d) for a given
cytokine, a specimen collected at two or more time
points after allergen challenge. When more than one
specimen was collected and analysed for the same
time point (e.g. report of cytokine level at 6 and 8 h
after allergen challenge), the largest of the values was
selected. This approach resulted in 358 contributions
extracted from 82 published articles.
Of these 358 contributions, 205 reported a sig-
nificant positive variation of the cytokine level when
comparing the post-allergen value with the control
value. By contrast, 149 articles reported no significant
variation and four reported a significant negative
variation. Therefore, the two latter categories were
collapsed into one category (no increase) for statis-
tical analysis.
This review does not involve a meta-regression
analysis. Rather, it provides a convenient summary of
studies that addressed similar questions using similar
study designs. To complement such a summary, a
binomial test for proportions was calculated to assess
the likelihood of obtaining the observed cytokine
data (i.e. number of studies reporting a significant
positive variation versus number of studies reporting
no increase) given an expected value predicted by
the null hypothesis (H0). The H0 was that the allergen
challenge had no effect on the cytokine level when
compared with the control. This H0 was translated
into the binomial probabilities of 0.05 (p, probability
of success) and 0.95 (q, probability of no success). An
observed set of cytokine data was considered to be
unlikely to occur under the H0 if the probability value
resulting from the binomial test for proportions was
B/0.001.
Results
Data description
Data reported here refer to 358 contributions ex-
tracted from 82 articles (mean contribution per
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uniform with respect to the atopy status of the
patients and the allergen used for challenge. Indeed,
98% involved a sample of atopic subjects and 91%
used a common allergen for challenge (grass, rag-
weed, birch, dust mite or pet extract). In addition to
the allergen type, the allergen concentration used for
challenge is known to affect the consequent severity
of the inflammatory response. However, there was no
consistent report of standardised values of allergen
concentration, which prevented such analysis. The
post-allergen cytokine value was compared with the
baseline or saline challenge value in 39% and 61% of
the cases, respectively. The studies reviewed here
involved on average 10 subjects per trial (range, 4 /35
subjects).
The 358 contributions included 200 fluid and 158
biopsy analyses. Ninety-one per cent and 84% of
these analysed cytokine protein level by immunoas-
says (mostly enzyme-linked immunosorbent assay)
and cytokine mRNA by in situ hybridisation, respec-
tively. The remaining contributions involved different
methods (e.g. immunohistochemistry) and, therefore,
were not used for subsequent analysis.
Cytokine protein expression in fluids
Studies that assessed free protein levels in fluids
provided quantitative data for 20 cytokines. However,
for only 13 cytokines was the sample size (i.e.
number of contributions) large enough to assure
sufficient power to reject the null hypothesis (power
]/0.9). Summary data for these cytokines, as well as
the references that provided the information, are
presented in Table 1.
Four points should be noted. First, there are eight
cytokines for which expression was analysed within
0 /1 h after allergen challenge. For all these, no
consistent positive variation was reported. Second,
six cytokines appear to be consistently up-regulated
in fluids at 4 /12 h after challenge. Four of these are
chemokines (eotaxin, macrophage inflammatory pro-
tein (MIP)-1a, RANTES (regulated on activation
normal T cell expressed and secreted) and IL-8).
Third, 18 /24 h after challenge, the lymphokines IL-4,
IL-5 and IL-13, as well as the pro-inflammatory
cytokines granulocyte /macrophage colony-stimulat-
ing factor (GM-CSF), tumour necrosis factor (TNF)-a
and IL-6 are consistently increased compared with
the respective control value. Finally, there was no
evidence that IFN-g is increased after challenge,
whereas two studies demonstrated a significant IL-2
increase. Cytokines reported by a small number of
studies (n5/2) are not presented in Table 1; these
include monocyte chemotactic protein (MCP)-1,
45,118
MCP-3,
25 macrophage-derived chemokine (MDC)
and thymus-regulated and activation-regulated che-
mokine (TARC),
16 transforming growth factor-a,
65 IL-
1a,
39 and IL-16.
58,92
Cytokine mRNA expression in biopsies
Most studies analysing cytokine mRNA in biopsies
quantified the number of mRNA-positive cells per
area of allergen-challenged tissue. This was usually
conducted 18 /24 h after challenge (Table 2). Of
special interest is the consistent report of significant
increases in mRNA positive cells for GM-CSF, IL-4, IL-
5 and IL-3 and, by contrast, the systematic reports of
no variation in IL-2 and IFN-g. The expression of IL-
10 and IL-13 mRNA was also shown to be up-
regulated by independent studies. Cytokines not
presented in Table 2 due to small sample size include
eotaxin,
20,69 MCP-3,
111 MIP-1a,
114 RANTES, IL-6 and
IL-8,
54,55 IL-12,
109 and IL-16.
60
Discussion
This systematic review provides a summary of the
published data reporting cytokine expression follow-
ing allergen-induced tissue inflammation. It aimed to
address two questions: Which cytokines are consis-
tently up-regulated in fluids or biopsies of allergen
challenged tissues in atopic patients? Is there a time-
dependent pattern of cytokine expression? Here, we
will point out how this knowledge can be used to
improve the understanding and the control of allergic
diseases.
First, no evidence could be found that cytokines
are consistently increased within 0 /1 h after allergen
challenge. Within this period atopic subjects are
known to experience an immediate hypersensitive
response, which is driven to a great extent by mast
cells and results in considerable tissue damage.
159
Since mast cells are known to release preformed
inflammatory cytokines upon activation,
160,161 it is to
some extent surprising that no cytokine was ob-
served to be consistently up-regulated within 0 /1h
after challenge.
Second, this review confirms previous individual
reports that the chemotactic cytokines eotaxin, MIP-
1a, RANTES and IL-8 are increased at a time point that
corresponds to the onset of the late phase allergic
reaction (4 /12 h; see reference 11). Third, the
inflammatory cytokines GM-CSF, TNF-a and IL-6,
and the lymphokines IL-3, IL-4 and IL-5 are found
to be significantly increased across a large number of
independent studies at 18 /24 h. Finally, IFN-g
protein and mRNA, and IL-2 mRNA have not been
reported to be increased by any of the studies here
reviewed. Although an attempt has been made to
avoid labelling cytokines as Th1-like or Th2-like, the
combined results presented here agree with the Th2
Cytokines in allergic inflammation
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other allergic diseases.
How can the conclusions from these studies be
used to improve the understanding and control of
allergic reactions?
Allergen challenge studies and the
immunobiology of allergic reactions
Different studies have highlighted the fact that
inflammatory cytokines are significantly increased in
tissues exposed to allergen. These could be consid-
ered the danger messages used by cells of the
immune system to sense a break in homeostasis.
One of such cytokines identified by allergen chal-
lenge studies is GM-CSF. This cytokine is secreted by
a variety of cells, including T cells, macrophages and
structural cells of the injured tissue.
162,163 It acts
pleiotropically with effects on target cells that include
proliferation and differentiation of haematopoietic
cells and activation of eosinophils.
164,165 Importantly,
GM-CSF has recently been shown to stimulate the
functional maturation and activation of dendritic cells
(DC) in vivo.
166,167 Together, these findings might
provide an important insight to the understanding of
the immunobiology of allergic reactions. Indeed, DC
are essential in the control of immunity.
168 Although
subject to considerable research at present,
169 the
maturation state of DC at the time of antigen
presentation to T cells in the lymph nodes seems to
be a key step that determines whether the organism
will develop tolerance or immunity against self-
Table 1. Variation of cytokine protein levels in ﬂuids collected after allergen challenge in atopic patients.
Positive variation
$ Disease status
% Challenge site
§ References
n\N asthma\rhinitis\other Lung\nose\skin
Eotaxin
4 /12 h 4\6
* 2\2\2 2\2\2 20,26,34,62,76,92
GM-CSF
0 /1 h 1\7 2\5\0 2\5\0 39,49,63,64,89,101
4 /12 h 5\8
* 1\5\2 0\5\3 33,34,63,66,76,89
18 /24 h 7\9
* 9\0\0 8\1\0 12,33,42,49,65,70,101,108
IFN-g
18 /24 h 0\3 3\0\0 3\0\0 65,101,102
MIP-1a
4 /12 h 3\3
* 1\1\1 1\2\0 26,45,89
RANTES
0 /1 h 1\3 0\1\2 0\2\1 76,89,92
4 /12 h 5\6
* 2\1\3 2\3\1 26,45,89,92,95,118
18 /24 h 2\3 2\0\1 2\1\0 26,45,90
TNF-a
0 /1 h 1\4 1\3\0 1\3\0 17,39,101
4 /12 h 0\3 0\2\1 0\2\1 39,118
18 /24 h 6\6
* 5\1\0 5\1\0 42,70,88,101,102
IL-1b
0 /1 h 1\3 1\2\0 1\2\0 64,89,101
18 /24 h 2\4 4\0\0 4\0\0 42,70,101
IL-2
18 /24 h 2\3 2\1\0 2\01 61,65,101
IL-4
0 /1 h 0\4 3\1\0 3\0\1 35,49,56,101
4 /12 h 3\3
* 0\3\0 0\1\2 35,76,104
18 /24 h 7\10
* 8\2\0 8\2\0 42,41,44,56,65,70,88,101,102,104
IL-5
0 /1 h 1\5 2\2\1 3\2\0 49,51,63,92,101
4 /12 h 3\6 2\3\1 2\3\1 34,43,63,82,92,93
18 /24 h 10\12
* 10\2\0 10\2\0 42,49,52,65,70,82,88,90,93,101,102
IL-6
0 /1 h 1\4 1\2\1 1\2\1 39,101,118
4 /12 h 3\6 1\4\1 0\4\2 33,39,61,104,118
18 /24 h 6\6
* 5\1\0 4\2\0 33,42,70,101,104
IL-8
0 /1 h 1\9 2\4\3 3\5\1 38,48,74,89,101,105,118
4 /12 h 7\11
* 4\4\3 3\7\1 53,38,48,74,80,82,89,96,118
18 /24 h 4\8
* 7\1\0 5\3\0 33,42,70,80,82,96,101
IL-13
18 /24 h 3\3
* 3\0\0 3\0\0 47,56,102
Each study involved both a control and a post-allergen challenge protein assay. The latter was performed in fluids collected 0 /1h ,4 /12 h or
18 /24 h after challenge. The number of studies (i.e. contributions, since some studies involve more then one subject sample; see Material and
methods for details) reporting a significant higher level of protein after challenge when compared with the control value is represented by n.
$ Number of studies (n) reporting a significant positive variation of cytokine level following allergen challenge. N: total number of studies
reporting cytokine data.
% Number of studies involving patients with asthma, rhinitis or other diseases.
§ Number of studies involving allergen challenge in the lung, nose or skin.
* pB/0.001, binomial test for proportions (see Methods and methods for details).
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169,170 DC mature
in peripheral tissues that secrete GM-CSF in response
to injury. Therefore, it is plausible that the stimulation
that DC receive in situ from this cytokine is a crucial
step that determines the efficiency of these cells to
prime antigen-specific immune responses. Impor-
tantly, the antigen presentation ability of DC might
not only be a function of the GM-CSF concentration
present in the microenvironment where it captured
antigen, but also a function of the GM-CSF receptor
allele that the cell expresses. This hypothesis has
recently received some support from patients with
lupus erythematosus. Indeed, dysregulation of the
GM-CSF receptor in antigen presenting cells was
found to be associated with a down-regulation of the
CD80 costimulatory antigen.
171 This could in turn
lead to a dysfunction of antigen presentation to T
cells. Although the GM-CSF receptor has been
implicated in lung homeostasis,
172 174 its role in the
development of primary immune responses is still
largely unknown.
Allergen challenge studies and the control of
allergic reactions
Allergen challenge studies have demonstrated that
chemotactic cytokines and lymphokines are signifi-
cantly increased as a result of allergen challenge.
Chemokines, such as eotaxin and MIP-1a, are re-
leased by immune and structural cells of the injured
tissue
175,176 and are responsible for the late recruit-
ment of eosinophils, neutrophils and basophils to the
site of inflammation.
177,178 This recruitment is an
essential step in the development of the late-phase
allergic response and, therefore, it represents a
candidate immunological mechanism to be targeted
by new therapeutical approaches. On the contrary,
MDC and TARC are potent attractants of polarised
Th2 cells.
179,180 Although the ‘Th2 hypothesis’ for
asthma or other allergic diseases is likely to be too
simplistic,
181,182 efficiently blocking the effects of
these cytokines could represent a plausible approach
to reduce the up-regulation of lymphokines such as
IL-4, IL-5 and IL-13. Therapeutic approaches invol-
ving blocking antibodies against specific cytokines
characteristic of allergic reactions have recently been
reported. Indeed, the injection of a monoclonal
antibody to IL-5 in allergic asthmatic volunteers
significantly reduced the number of eosinophils in
blood and sputum.
183 Although no changes were
observed in the magnitude of the late-phase re-
sponse, this clearly demonstrated that efficient in
vivo blockage of cytokine effects in allergic asth-
matics can drastically influence specific immunologi-
cal mechanisms.
This review confirms that inflammatory cytokines
such as GM-CSF, TNF-a and IL-6 are increased in
tissues of atopic patients exposed to allergen. There-
Table 2. Variation of cytokine mRNA expression in biopsies collected after allergen challenge in atopic patients.
Positive variation
$ Disease status
% Challenge site
§ References
n\N asthma\rhinitis\other lung\nose\skin
GM-CSF
18 /24 h 7\7
* 2\2\3 1\4\2 15,30,32,72,79,91,100
IFN-g
0 /1 h 0\3 0\2\1 0\2\1 54,55,99
18 /24 h 0\10 1\4\5 1\6\3 15,30,32,54,55,68,72,99,100,112
TNF-a
18 /24 h 2\4 0\2\2 0\3\1 54,55,115
IL-2
0 /1 h 0\3 0\2\1 0\2\1 54,55,99
18 /24 h 0\8 1\2\5 1\5\2 15,30,32,54,55,68,99,100
IL-3
18 /24 h 5\7
* 2\2\3 1\4\2 15,30,32,54,55,91,100
IL-4
0 /1 h 1\3 0\2\1 0\2\1 54,55,99
4 /12 h 4\5
* 2\1\2 1\1\3 14,43,78,99,110
18 /24 h 15\18
* 4\5\9 2\9\7 14,15,24 /32,37,54,55,68,72,77,91,99,100,110,112,116
Il-5
0 /1 h 1\3 0\2\1 0\2\1 54,55,99
4 /12 h 2\4 2\1\1 1\1\2 14,43,78,99
18 /24 h 10\13
* 3\5\5 1\7\5 14,15,30,32,54,55,68,72,91,99,100,112,117
IL-10
0 /1 h 2\3 1\2\0 0\2\1 54,55,87
IL-13
18 /24 h 2\4 0\3\1 0\4\0 36,54,55,72
Cytokine mRNA expression was assessed by in situ hybridization. Each study compared the number of positive cells observed in biopsies taken
after challenge with the respective value observed in the control biopsy.
$ Number of studies (n) reporting a significant positive variation of cytokine level following allergen challenge. N: total number of studies
reporting cytokine data.
% Number of studies involving patients with asthma, rhinitis or other diseases.
§ Number of studies involving allergen challenge in the lung, nose or skin.
* pB/0.001, binomial test for proportions (see Methods and methods for details).
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antigen capture and antigen presentation in vivo by
DC should be further investigated. In addition, it is
also shown that different lymphocyte-derived cyto-
kines are significantly increased after allergen chal-
lenge. Thus, the development of new strategies for
allergic disease control should consider the effects of
blocking chemokines that target specific lymphocyte
subtypes, such as MDC or TARC. Data concerning the
expression of these chemokines following allergen
exposure is scarce and, therefore, should be ad-
dressed by future allergen challenge studies.
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